• Hilary Miller-Handley, Keith Luckett, and Amit Govil.
• Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH.
• Adv Chronic Kidney Dis. 2020 Sep 1; 27 (5): 434-441.

AbstractCoronavirus disease 2019, the disease caused by the severe acute respiratory syndrome coronavirus 2 virus, was first identified in the Hubei Province of China in late 2019. Currently, the only role for therapy is treatment of the disease, as opposed to postexposure prophylaxis, however multiple clinical trials are currently ongoing for both treatment and prophylaxis. Treating coronavirus disease 2019 relies on two components; the first is inhibition of the viral entrance and replication within the body and the second is inhibition of an exacerbated immune response which can be seen in patients with severe disease. Many drugs have shown in vitro antiviral activity; however, clinical trials have not been as promising. This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD. While clinical trials are ongoing, most are in patients with normal kidney function. During a pandemic, when patients with CKD are at higher risk of both infection and death, it is imperative to include patients these patients in the clinical trials.Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

64 keywords...

hide…